
Piramal Pharma Ltd. share price
NSE: PPLPHARMA · Healthcare
₹244.93 +0.16%
Closing price data, updated 17 Nov 2026. 52-week range: -3.5% from high, +85.1% above low.
Price₹244.93
Market cap₹32,480 Cr
P/E–
P/B3.99
ROE-4.0%
ROCE1.2%
Debt / equity0.70
Dividend yield0.00%
EPS₹-1.57
Book value₹61.40
Operating margin1.8%
Dipscan score24 / 100
Share: WhatsAppX / TwitterTelegram
Piramal Pharma Ltd. shareholding pattern
As of Sep 2026: Promoters 34.80%, FIIs 13.65%, DIIs 14.44%, Government 0.00%, Public 13.27%, Others 23.84%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 34.80% | 34.80% | 34.86% | 34.86% | 34.86% | 34.86% |
| FIIs | 13.65% | 12.52% | 30.18% | 29.66% | 30.27% | 30.86% |
| DIIs | 14.44% | 14.57% | 15.61% | 15.69% | 14.89% | 14.26% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 13.27% | 14.54% | 13.74% | 14.11% | 19.47% | 19.45% |
| Others | 23.84% | 23.57% | 5.61% | 5.69% | – | – |
| No. of Shareholders | 413,197 | 461,096 | 450,661 | 453,830 | 462,511 | 458,430 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +0.16% | +2.34% | +26.29% | +15.17% | +40.31% | +26.11% |
Growth
| Sales growth, 3 years | +7.6% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | – |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Weaknesses
- Stock is trading at 4.00 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.03% over past five years.
- Company has a low return on equity of -0.88% over last 3 years.
- Company might be capitalizing the interest cost
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Piramal Pharma Ltd.?
Piramal Pharma Ltd. (PPLPHARMA) last closed at ₹244.93 (+0.16% on the day).
What is the market cap of Piramal Pharma Ltd.?
About ₹32,480 Cr.
What is the P/E ratio of Piramal Pharma Ltd.?
The price-to-earnings ratio is –, and return on equity is -4.0%.
Figures are calculated from company results and exchange prices and are for information only.